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VIEWPOINT 
The Social Value Of 
Vaccination Programs: 
Beyond Cost-Effectiveness 
 
 
Abstract 
In the current global environment of increased strain on 
health care budgets, all medical interventions have to 
compete for funding. Cost-effectiveness analysis has 
become a standard method to estimate how much value an 
intervention offers relative to its costs, and it has 
become an influential element in decision making. 
However, the application of cost-effectiveness analysis 
to vaccination programs fails to capture the full 
contribution such a program offers to the community. 
Recent literature has highlighted how cost-effectiveness 
analysis can neglect the broader economic impact of 
vaccines. In this article, we also argue that 
socioethical contributions such as effects on health 
equity, sustaining the public good of herd immunity, and 
social integration of minority groups are neglected in 
cost-effectiveness analysis. Evaluations of vaccination 
programs require broad and multidimensional perspectives 
that can account for their social, ethical and economic 
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impact as well as their cost-effectiveness.  
 
 
Edward Jenner, at the time a physician in the 
English countryside, scientifically demonstrated the 
principle of vaccination in 1796 (using cowpox pus 
against smallpox). The ensuing gradual wide-scale use of 
this principle in Europe and later in the rest of the 
world, made a phenomenal contribution to human well-
being.[1,2] For instance, in the United States, vaccines 
were shown to have prevented 103 million cases of 
selected infectious diseases, including forty million 
cases of diphtheria (since 1924) and thirty-five million 
cases of measles (since 1963).[3] Currently, an estimated 
80–90 percent of the world’s children receive the basic 
package of vaccines from the World Health Organization’s 
(WHO’s) Extended Program on Immunization (up from 15 
percent initially in the 1980s).[4,5] Smallpox was 
eradicated in 1977, and rinderpest, a cattle disease, in 
2011.[6] Polio has been eliminated from the United States 
and Europe.[2]  
Despite these historical successes, vaccination is 
not just a story from the past. Stanley Plotkin and 
colleagues enumerated twenty-two diseases and infections 
for which effective vaccines exist but also forty-seven 
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others for which sufficiently effective vaccines are 
currently not available.[7] Infectious diseases, many of 
which are vaccine preventable, remain a leading cause of 
worldwide mortality.[8] For instance, approximately 6.3 
million children under 5 die each year, and about half of 
these deaths are due to pneumonia (often caused by 
influenza or pneumococcus), diarrhea (often caused by 
rotavirus) or other diseases caused by potentially 
vaccine-preventable infections such as measles, tetanus, 
tuberculosis and malaria.[2,8] Current realities such as 
global warming, globalization, and increased urbanization 
all facilitate disease transmission. Global warming 
changes environments and allows for organisms to flourish 
in previously inhospitable environments.[9] Populations 
are more mobile, and globalization and increased 
urbanization allow for greater movement of people and 
microbes, thus contributing to disease transmission. 
Perhaps an even greater issue is antibiotic 
 resistance, which reduces the ability to cure many 
common acute infections compounded by a lack of having 
real alternative treatments in development.[10] Wider and 
inappropriate use of antibiotics promotes antibiotic 
resistance. The prevention of infections through 
vaccination reduces the need to treat infections with 
antibiotics. Such treatment can be appropriate when these 
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infections are caused by bacteria (eg, Streptococcus 
pneumoniae, Bordetella pertussis; both vaccine-
preventable). Antibiotic treatment is often inappropriate 
when it is used against infection with viruses (eg, 
influenza).  
Given their continued importance in reducing the 
global infectious disease burden and curtailing 
antibiotic resistance, there is little doubt that 
vaccination will remain a pillar of public health. It is 
essential to have adequate policy environments in place 
that can guarantee a timely and steady supply of vaccines 
along with well-established pathways to enable their 
widespread uptake in the population. A key for success is 
to secure sufficient financial resources for vaccination. 
In the current context of rising pressure worldwide on 
health care budgets, where all medical interventions have 
to compete for funding, success can only be guaranteed by 
correctly understanding the value vaccination offers to 
the community. When policy makers only see part of the 
benefits of a vaccine but all of its costs, they are 
likely to underinvest. Not only would this lead to 
suboptimal use of existing vaccines, it would also 
adversely affect the supply of new vaccines as their 
development and production is very expensive and risky. 
In addition, since their production occurs predominantly 
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in a private market, it is important that vaccines remain 
an attractive business opportunity with a sufficient 
return on investment.[7]  
 
Cost-Effectiveness And Broader Economic Impact  
Cost-effectiveness analysis has become a standard 
framework for evaluating health care interventions in 
terms of value for money, by comparing their incremental 
costs with their incremental health effects (usually 
expressed as a cost per quality-adjusted life-year [QALY] 
gained).[11] Although official guidelines and regulations 
stipulate that funding decisions should not be based on 
cost-effectiveness alone, it has become an important 
predictor of funding decisions.[12] Cost-effectiveness is 
often referred to as the “fourth hurdle” a health program 
has to take in order to qualify for funding, after having 
demonstrated safety, quality, and efficacy.[13] Many 
countries have made evidence of cost-effectiveness 
mandatory in decision making on subsidized health care, 
including vaccines (for example, Australia, Finland, 
Norway, Canada, Portugal, Sweden, the Netherlands, and 
the United Kingdom).[14] In other countries such as the 
United States, cost-effectiveness analysis is not 
mandatory and its role is more limited. However, its 
implementation is nonetheless a subject of 
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discussion,[15,16] and in the context of infectious 
disease prevention cost-effectiveness analysis is often 
used as a means to make informed decisions.[17,18]   
Vaccination is in several ways a special health care 
intervention.[14] Vaccines work preventatively, are 
usually administered to otherwise healthy individuals, 
often at a very young age, but give a (small) risk of 
serious adverse effects in vaccine recipients. Ideally, 
vaccination programs are rolled out with a long term 
population-wide public health goal in mind, taking 
account of its often substantial-– mostly positive and 
protective -– indirect effects in unvaccinated groups of 
the population (eg, neonates, immunosuppressed and 
elderly) through the population-wide reduction in the 
circulation of vaccine-preventable pathogens . Some of 
these properties may also be present in other forms of 
health care (for example, smoking cessation programs are 
preventative and may yield health effects in non-
smokers), but their concentration in one intervention is 
unique to vaccination. A relevant question is, therefore, 
whether a one-size-fits-all evaluation method such as 
cost-effectiveness analysis manages to adequately take 
into account these particular characteristics.  
During the past decade, several researchers have 
indeed argued that cost-effectiveness analysis can 
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misrepresent the real economic value of vaccines.[14,19-
27] These scholars argue that cost-effectiveness analysis 
wrongly restricts itself to a “narrow” focus, 
underestimating the longer-term and broader economic 
effects of vaccines by only measuring short-term health 
care and productivity costs during the illness and its 
sequelae and by only considering effects on the 
vaccinated individual and closely related individuals 
(such as caregivers) instead of larger populations.  
Recently, efforts have been made to develop economic 
frameworks that adopt a “broader” focus than cost-
effectiveness analysis and that can consider the full 
economic impact of vaccines (e.g. 21,23,27). The broader 
benefits that are considered in these frameworks 
typically involve longer-term effects and wider 
externalities beyond the vaccinated individuals or their 
caregivers, such as increased lifetime productivity 
because of enhanced capabilities that are not easily 
measured, for example, improved cognition and educational 
attainment as a result of absence of infection and 
disease at a young age; ecological effects, such as 
reduced antibiotic usage and resistance; programmatic 
synergies, such as the development of delivery platforms 
that could be used for other purposes than vaccination, 
for example, health or social care communication; or 
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macroeconomic effects. The latter includes changes in 
household consumption and foreign investments due to 
uncertainty and risk-aversion caused by infectious 
diseases, as well as large demographic changes that 
impact on labor supply.[28] Such extended frameworks may 
also be relevant for other public health programs or 
complex interventions with important consequences that 
are difficult to measure or value unambiguously.  
 
Social Impact  
When it comes to priority-setting decisions and 
health care budget allocation, few will argue that cost-
effectiveness and economic welfare should be the only 
guiding principles. The societal value of a vaccination 
program beyond cost-effectiveness and economic welfare is 
also in part determined by its impact on other objectives 
of public policy, such as promoting health equity, 
sustaining public goods, and stimulating social 
integration. Depending on the specific context, 
vaccination programs can play an important positive or 
negative role in achieving these goals. 
 
Promoting Health Equity  
In the most recent decades, health equity--fairness 
in the distribution of health within a population--has 
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become an increasingly important social policy objective. 
Vaccination programs can affect equity on two levels: 
between socioeconomic groups and between generations.  
Both across and within country borders, along 
several axes of social stratification (e.g. education, 
income, occupation), it is systematically observed that 
the better-off population have better health prospects 
than the worse-off population.[29] There is a wide 
consensus that addressing this “social gradient” in 
health status should be a policy priority. However, 
affecting the social gradient presents obstacles, since 
it can be hard to identify the specific areas where 
action is most needed. First, from an effectiveness point 
of view: What can be done? In many instances, such as 
when trying to address disparities in cancer rates, the 
causal pathway to achieving more equality can be 
difficult to uncover. Second, from an ethical point of 
view, it can be difficult to single out areas where 
action should be undertaken. Not all health inequalities 
are necessarily inequities. For instance, inequalities 
between different income groups can be the result of 
complex social mechanisms beyond individual control, but 
they can also be the consequence of autonomous individual 
choice (for example risky lifestyle choices), which will-
-at least to some--be a morally relevant distinction to 
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make. From a health equity perspective such distinctions 
between avoidable and unavoidable and between fair and 
unfair inequalities matter, and only those that are both 
avoidable and unfair imply an undisputable call for 
policy measures and additional public resources.  
In the case of infectious diseases, there is a 
strong presumption that inequalities indeed fall into the 
avoidable and unfair category and are amenable to 
interventions. First, disparities in infection rates are 
relatively easy to counter through more inclusive 
vaccination programs.[30,31] Moreover, infections are 
rarely reducible to lifestyle choices for which 
individuals could be held responsible. Few infections are 
related to chosen behaviors (infections transmitted by 
unsafe sex or injecting drug use might qualify), and, as 
most vaccines are offered during childhood, the choice to 
become vaccinated or not is rarely a decision for which 
an individual can be held personally accountable. 
Therefore, large-scale vaccination programs are essential 
instruments to promote health equity as they level the 
health risks that different socioeconomic groups face 
before issues of lifestyle and personal responsibility 
become relevant. 
Moreover, there is substantial evidence that many 
other health conditions (or even inequalities in wealth 
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and well-being) later in life (part of which will again 
qualify as being inequitable) are related to a bad start 
in childhood,[32] for example, through experiencing a 
severe episode of an infection, such as childhood 
meningitis or congenital rubella syndrome. A general 
recommendation of the WHO’s commission on social 
determinants of health is, therefore, to strengthen the 
role of prevention,[33] and several authors argue that 
vaccination should be a priority in this.[34]  
But equity can also be relevant on an 
intergenerational level. The benefits, risks, and 
opportunity costs of a vaccination program are not 
necessarily fairly spread over different age groups and 
generations. Examples include disease-eradication 
programs where the benefits potentially extend to 
infinity, whereas risks and costs have to be incurred in 
the present;[35] “altruistic” vaccination (for instance, 
annual influenza vaccination in children that 
substantially decreases the risk of influenza in all age 
groups); and “egocentric” vaccination, which yields 
health gains in one generation but risks to induce health 
losses in another (for instance, childhood varicella-
zoster virus vaccination, which may decrease chickenpox 
in children but simultaneously increase shingles in 
adults and the elderly[36,37]). Neglecting such 
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considerations can, depending on views about what 
different generations owe to each other, lead to 
inequitable vaccination policy and affect a general sense 
of intergenerational solidarity in preventing infectious 
diseases.   
Such considerations of socioeconomic or 
intergenerational equity are not considered in cost-
effectiveness analysis nor in frameworks for vaccines’ 
broader economic impact. Health outcomes (such as QALYs) 
are given an equal value, regardless of whether they 
improve health equity, widen disparities even further 
(for example, by improving the health of better-off 
groups only), or harm the rightful interests of 
particular generations or age groups. 
 
Sustaining The Public Good Of Herd Immunity  
Herd immunity is the disease protection that those 
individuals in a population who are immune offer to the 
remaining susceptible ones. It arises as a consequence of 
the reduced circulation of a pathogen that is observed 
when more and more individuals become immune, either 
through having experienced an infection or through 
vaccination.[38]  
This herd immunity is an important way of protecting 
two groups of individuals who are unable to protect 
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themselves. First, vaccines can only be effectively 
administered to those individuals with an immune system 
that is able to trigger an adequate antibody response. 
Young infants, the elderly, pregnant women, patients with 
chronic illness, or those with particular allergies often 
do not tolerate vaccination. Second, also to 
immunocompetent individuals, vaccination does not offer 
(on average) 100 percent protection. There is always a 
percentage of those who are vaccinated who are not 
protected against the disease (because of an ineffective 
vaccine or unsuccessful response from the immune system). 
No one can be 100 percent certain that a vaccine he or 
she receives will work for him or her. In other words, 
herd immunity is an important benefit to everyone at any 
time. As we have all been children, and we expect to be 
old one day, and as we cannot be certain about our 
protection in the lifetime in between, we all benefit 
from herd immunity at different stages in our lifetime. 
It should be seen as a safety net for unfortunate 
individuals, an essential second tier of infectious 
disease prevention.  
This herd immunity should be considered as a “public 
good.”[39,40] It offers a substantial benefit to the 
entire population, but establishing and maintaining it 
requires collective action. This dependence on collective 
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effort makes a public good vulnerable, difficult to 
establish, and demanding to sustain. In the case of herd 
immunity, it requires broad support and dedication from 
the population to collectively undergo short-run 
sacrifices (costs and possible adverse effects from 
vaccinations) for more long-term and less visible herd 
immunity benefits. At the same time, on an individual 
level, people will have an incentive to “free ride” on 
the efforts of others: Let others become vaccinated and 
risk adverse effects and then take advantage of their 
efforts.[40]  
A key responsibility of public policy is to 
establish these public goods but also, once they are 
there, to manage the complex social dynamics that are 
involved in sustaining them.[41] Considerations of trust, 
goodwill, solidarity, and fairness are essential to long-
term success. Vaccination programs have characteristics 
that can affect these values and that can consequently 
affect the public good of herd immunity.  
First, although vaccines are generally considered to 
be safe, all vaccines can cause side effects, which are 
usually mild. Serious adverse events also occur, albeit 
rarely. But the occurrence of the latter can have an 
extraordinary and unpredictable impact on public 
perception and can disproportionally affect the 
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acceptance and success of a vaccination program, other 
vaccines, or any intervention co-administered with it. 
Public scares such as with the measles, mumps, and 
rubella vaccine in the United Kingdom, can have long-
lasting effects on overall vaccine uptake that are costly 
and hard to counter.[42] There is a large symbolic or 
role-model dimension to the safety of a vaccination 
program, and the impact of serious adverse effects goes 
widely beyond their actual health consequences. Moreover, 
in the present context of internet and social media, 
where antivaccination lobbies are increasingly inflating 
such risks over the benefits, or spreading completely 
false allegations, harmful consequences may even be 
exacerbated . [43, 44] 
A second element is the perceived extent of free-
riding in a program. Once herd immunity is established, 
it is difficult to exclude free-riders from benefitting 
from it. If the public perception is that large groups of 
people free ride (either intentionally or 
unintentionally, such as in the case of religious vaccine 
refusers), then this can affect the willingness of others 
to contribute. But also, vice versa, if the perception is 
that those people who can become vaccinated overall do 
so, that sacrifices for the public good are generally 
fairly distributed, and that free-riding is a marginal 
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phenomenon, then this can establish a social norm to 
contribute to the creation of herd immunity. These norms 
signal appropriate behavior, reinforce it, and are 
influential determinants of success in establishing and 
maintaining public goods.[45]    
This public good dimension of a vaccination program 
is not properly accounted for in cost-effectiveness 
analysis. Many analyses are based on static models that 
ignore the herd immunity benefits a program 
generates.[46] Increasingly, cost-effectiveness analyses 
use dynamic transmission models,[46-49] which do consider 
cases prevented indirectly through herd immunity but do 
not adequately take into account the complexity of 
positive values of herd immunity and the factors that 
sustain or undermine it. Adverse health effects are 
valued in a similar way as the positive effects from 
vaccination (for example, in QALYs gained versus lost and 
supplementary treatment costs) without considering their 
costly repercussions of losing trust and goodwill. Herd 
immunity benefits are valued by simply assigning QALYs to 
them, irrespective of whether those who receive them are 
in fact free-riders or vulnerable individuals who can’t 
protect themselves, and no valuation is provided for 
social norms or contributing to the public good.  
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Social Integration Of Minorities 
A third broader social objective in which 
vaccination can play an important positive or negative 
role is the social integration and inclusion of ethnic or 
cultural minorities. Both in the United States and in the 
European Union, policy makers acknowledge that this is a 
big and ongoing social challenge that requires positive 
action and targeted policies.[50] In the European Union, 
the current migrant crisis makes this objective 
especially poignant.  
Vaccination can foster integration by countering 
social dynamics such as stigmatization that can be fueled 
by infectious disease transmission. Population subgroups 
with a sensitive public image often also have higher 
incidence of and more severe disease from infections.[51-
54] Examples include measles in Europe’s Roma population; 
hepatitis A in men who have sex with men and in immigrant 
clusters in Europe among those from the (Maghreb) 
Northwest African countries of Morocco, Algeria, and 
Tunisia; hepatitis B in sex workers; and several 
infections, such as rotavirus, pneumococcus, hepatitis A, 
and hepatitis C in indigenous populations in Australia 
and North and South America. Arguably, these transmission 
patterns can hinder social mobility, integration, labor 
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market participation, or, worse, create an atmosphere of 
exclusion in the community at large.  
On the other hand, the opposite is also 
conceivable.[55,56] Vaccination programs targeted 
specifically at these minorities could be perceived as 
discriminatory, by the target group who may feel unfairly 
singled out for vaccination or by the majority who has to 
pay more for the vaccine. Or, it could reinforce 
stigmatizing stereotypes that minority groups are 
responsible for the transmission of particular diseases 
in the community.  
These subtleties affect the broader social impact of 
a program but are neglected in an appraisal based on 
cost-effectiveness or broader economic impact.  
 
Conclusion 
In a context of increasingly strained health 
budgets, in which cost-effectiveness analysis and 
comparative effectiveness research have become 
influential drivers of funding decisions (especially in 
Europe but increasingly in the United States as well), it 
is important to correctly understand the full 
contribution vaccination programs offer to the community 
and the extent to which this value is over- or 
underestimated in summary measures such as cost per QALY. 
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Several authors have argued that vaccines can have a 
broader economic impact than other health care 
interventions and that their value is underrepresented in 
cost-effectiveness analysis (14,19-27). In this article, 
we argued that vaccination programs also have a special 
relationship with particular objectives of social policy. 
An important but admittedly difficult challenge for 
health technology assessment and appraisal is to expand 
existing methods so that they manage to include these 
broader, complex, and often multidimensional effects.[57] 
However, in absence of more complete evaluation 
frameworks, decision makers should be aware of the social 
benefits and costs of vaccination that are excluded.  
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